ストックスクリーナーアプリを入手
1.92
1.63%
-0.03
前日終値:
$1.95
開ける：
$1.94
24時間の取引高:
41,956
Relative Volume:
0.33
時価総額：
$149.05M
収益：
-
当期純損益:
$-19.57M
株価収益率:
-0.6134
EPS:
-3.13
ネットキャッシュフロー:
$-17.24M
1週間 パフォーマンス:
+14.86%
1か月 パフォーマンス:
-6.43%
6か月 パフォーマンス:
-41.70%
1年 パフォーマンス:
+58.53%
1日の値動き範囲:
$1.85
$1.9676
1週間の範囲:
$1.56
$2.0353
52週間の値動き範囲:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
名前
Inhibikase Therapeutics Inc
セクター
電話
678-392-3419
住所
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
IKT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.92 | 149.05M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.19 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.80 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.59 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
549.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.51 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-12 | ダウングレード | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc (IKT) 最新ニュース
Squarepoint Ops LLC Acquires Shares of 28,411 Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Millennium Management LLC Invests $462,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Northern Trust Corp Invests $208,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Inhibikase Therapeutics Insider Buyers Pleased With US$788k Return On Investment - simplywall.st
Inhibikase Therapeutics Reports Q1 2025 Financial Results - TipRanks
13,129 Shares in Inhibikase Therapeutics, Inc. (NYSE:IKT) Purchased by Stifel Financial Corp - Defense World
Inhibikase Therapeutics: Strategic Realignment and Financial Strength Justify Buy Rating - TipRanks
Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibikase Therapeutics, Inc. SEC 10-Q Report - TradingView
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Reports $93M War Chest, Accelerates Revolutionary PAH Treatment Development - Stock Titan
Barclays PLC Purchases New Holdings in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Former Inhibikase leader launches new biotech for midstage Parkinson's asset - Fierce Biotech
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT) - PR Newswire
Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH - Seeking Alpha
Geode Capital Management LLC Purchases 272,813 Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
IKTInhibikase Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
In wake of Anthos buyout, CFO McIntyre joins Inhibikase - biocentury.com
Inhibikase Therapeutics Advances PAH Treatment with New Leadership - TipRanks
Inhibikase Therapeutics appoints new CFO By Investing.com - Investing.com South Africa
Inhibikase Therapeutics Names David McIntyre as CFO - marketscreener.com
Inhibikase Therapeutics Announces Appointment Of David Mcintyre As CFO - marketscreener.com
Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise - MSN
Inhibikase Therapeutics appoints new CFO - Investing.com Australia
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewswire
Strategic Hire: Venture Capital Veteran and Life Sciences CFO Expert Takes Helm at Inhibikase - Stock Titan
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
In the wake of Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) latest US$29m market cap drop, hedge funds owners may be forced to take severe actions - simplywall.st
Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses - Yahoo
H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock - Investing.com India
HC Wainwright Reaffirms “Neutral” Rating for Inhibikase Therapeutics (NYSE:IKT) - Defense World
Inhibikase Therapeutics' (IKT) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Therapeutics Inc. (IKT) reports earnings - Quartz
Inhibikase Secures Future: $110M Funding, FDA Green Light, and New Leadership Fuel Growth - Stock Titan
INHIBIKASE THERAPEUTICS Earnings Preview: Recent $IKT Insider Trading, Hedge Fund Activity, and More - Nasdaq
Inhibikase Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research
After leaving FDA, Cavazzoni joins Pfizer as CMO - BioCentury
Inhibikase enhances leadership with new appointments By Investing.com - Investing.com Nigeria
Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewswire
Inhibikase Therapeutics, Inc. Announces Management Appointments -February 24, 2025 at 08:00 am EST - Marketscreener.com
Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals - TipRanks
Inhibikase enhances leadership with new appointments - Investing.com
Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World
Inhibikase Therapeutics Appoints Mark Iwicki as New CEO - TipRanks
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire
Inhibikase Therapeutics Inc (IKT) 財務データ
収益
当期純利益
現金流量
EPS
Inhibikase Therapeutics Inc (IKT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
1.35%
0.39%
大文字化:
|
ボリューム (24 時間):